Last updated: December 9, 2020
Sponsor: Novartis Pharmaceuticals
Overall Status: Terminated
Phase
2
Condition
Pulmonary Arterial Hypertension
Stress
Vascular Diseases
Treatment
N/AClinical Study ID
NCT02939599
CQCC374X2201E1
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Written informed consent must be obtained before any assessment is performed.
- Subject was enrolled in the QCC374X2201 study and completed per protocol
Exclusion
Exclusion Criteria:
- Subjects who have started receiving prostacyclin (epoprostenol), prostacyclin analogs (i.e. trepostinil, iloprost, beraprost) or prostacyclin receptor agonists (i.e.selexipag) since the last study drug intake in the QCC374X2201 study.
- Females who are pregnant, or who plan to become pregnant during the study, or who arebreastfeeding
- Any known factor or disease that may interfere with treatment compliance or studyconduct (i.e. drug or alcohol dependence)
- Subjects who withdrew consent from the study QCC374X2201
Study Design
Total Participants: 5
Study Start date:
February 01, 2018
Estimated Completion Date:
November 06, 2018
Connect with a study center
Novartis Investigative Site
Dresden, 01307
GermanySite Not Available
Novartis Investigative Site
Heidelberg, 69120
GermanySite Not Available
Novartis Investigative Site
Cambridge, Cambridgeshire CB23 3RE
United KingdomSite Not Available
Novartis Investigative Site
Pittsburgh, Pennsylvania 15261
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.